Board summary
Key figures
60,327
Registered population
59.5% aged 18–64
17.6%
Aged 65+
ICB 19.9% · England 17.9%
7.5%
Ethnic minority (non-White)
1.8% Asian · England 9.6%
15.2%
In IMD quintile 1
ICB 17.1% · England 21.0%
~9,324
Core20 residents (est.)
Resident basis; registered basis ~8,999 · see page 3
9,773
Hypertension register
+8.36% in 3 yrs · England +5.60%
494
SMI register
41.3% of Swale's
1,185
COPD register
Reviews +5.99% in 3 yrs
Forecast to 2030
12,368
Hypertension patients, 2030
+2,595 on today
76.8%
QRISK ≥20% on statins, 2030
+5.76pp over 3 yrs
4.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Pre-school MMR second dose drop-off at five.
At age 5, MMR coverage drops 6.5 pp from 93.0% (dose 1) to 86.5% (dose 2), which may reflect recall gaps to test locally.
Heart failure and asthma reviews trail England.
Three-year heart failure reviews fell 1.5% (England +8.7%), and 62.5% asthma review coverage leaves about 1,300 of 3,454 patients unreviewed, which may reflect recall.
Breast screening and cardiovascular therapy gains.
Three-year breast screening coverage rose +31.4% to 73.7% (England +8.4%), while QRISK ≥ 20% lipid therapy rose +10.0% to 63.5% (England +6.2%).
Population, age and ethnicity
Sittingbourne has 22.8% aged 0-17, exceeding Swale, ICB, and England comparators
Sittingbourne PCN serves 60,327 registered patients across its member practices. Children aged 0-17 represent 22.8% of the list (13,770 patients), exceeding Swale (22.0%), NHS Kent and Medway ICB (20.7%), and England (19.6%). Patients aged 65+ account for 17.6% (10,642 patients), below Swale (18.2%), the ICB (19.9%), and England (17.9%). Census usual residents are 92.5% White (Swale 93.8%, ICB 88.6%, England 81.1%), with 7.5% ethnic minorities. Projected list growth to 2030 is 5.8% under an unverified method. This younger profile may increase paediatric demand, which practice activity audits could test.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Swale local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Swale LA) | 1,484 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.1% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 54.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Swale LA) | 686 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Swale LA) | 19.1 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 15.2% of patients but practice shares span 20.7 percentage points
Sittingbourne PCN's Core20 share of 15.2% is below Swale (25.7%), NHS Kent and Medway ICB (17.1%) and England (21.0%), with an average IMD decile of 4.9 (Swale 4.4, ICB 5.4, England 5.5). The Chestnuts Surgery has a Core20 share of 20.7% across a practice range of 20.7 pp, while The Medic Care Surgery has 0.0%. Memorial Medical Centre holds the largest volume with 2,634 estimated patients, whereas The Chestnuts Surgery has 1,972 estimated patients. Practice estimates sum to 8,999 (14.9% weighted share). Outreach should balance practice deprivation concentration against absolute.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
494
SMI register
0.83% recorded prevalence
542
Learning disability register
0.91% recorded prevalence
23
Care homes, 528 beds
In the PCN catchment
9.9%
Provide unpaid care
Swale, Census 2021
The PCN records 542 learning disability patients (0.9% prevalence vs 0.8% Swale, 0.6% ICB, 0.6% England), comprising 43.6% of Swale's register, alongside 494 severe mental illness patients (41.3% of borough caseload). The catchment includes 23 care homes with 528 beds, although bed counts do not establish resident registration. With learning disability prevalence above England, sustaining dedicated annual health check capacity is the principal priority.
Severe mental illness: physical health checks
SMI blood pressure checks reached 79.2% (England 83.4%), BMI checks 81.0% (England 82.1%), and alcohol recording 76.8% (England 81.8%). Trailing national benchmarks across these checks may reflect recall routines, which practice audits could test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,773
Hypertension register
+8.36%
Register growth, 3 yrs
Swale +5.38% · England +5.60%
+4.21pp
BP control, under 80
≤140/90 · −0.59pp aged 80+
+2,595
More patients by 2030
Forecast 12,368 (19.31%)
Hypertension case-finding and control
Recorded hypertension prevalence is 16.4% (9,773 patients), compared with 17.0% in Swale, 16.2% in NHS Kent and Medway ICB, and 15.2% in England. Hypertensive patients treated to target reached 69.0% (England 70.3%), rising +6.0% from 2023 to 2025 (England +3.6%). Blood pressure control among patients aged 80 and over reached 76.9% (England 81.2%), but fell 0.8% from 2023 to 2025 (England +2.2%). Observation periods for current prevalence were not captured. This lag may reflect recall or treatment regimens, which clinical register audits could test.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 63.5% (Swale 64.2%, England 63.6%, ICB 61.4%), rising +10.0% from 2023 to 2025 (England +6.2%). This may reflect local initiation routines, which practice-level audits could test.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 85,293 | £2.50 | £1.90 | £1.86 | £213,232 |
| Cardiovascular (all), 2025 | 108,130 | £2.80 | £3.57 | £3.33 | £302,764 |
In 2026, the PCN prescribed 85,293 lipid-modifying items at £2.50 per item (Swale £2.32, ICB £1.90, England £1.86), spending £54,588 more than at England's unit cost. Higher unit cost than comparators could reflect formulary choices, which a medicines optimisation review would test.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+2.59%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.16%
Asthma prevalence, PCN 3-yr % change
Sittingbourne PCN's asthma register has 3,454 patients (6.2% prevalence, England 6.6%). Its 12-month asthma review rate of 62.5% trails England (65.7%) and Swale (63.4%), leaving about 1,300 patients unreviewed. The COPD register (1,185 patients; 2.0% prevalence) fell 0.7% from 2023 to 2025 (England +2.6%, Swale +0.2%), while COPD reviews reached 75.9% (England 76.4%). This pattern may reflect recall routines, which register audits could test.
Cancer register and children's immunisation
In Q1 2025/26, MMR coverage at age 5 dropped 6.5 pp from dose 1 (93.0%) to dose 2 (86.5%), which is below the 95% target by 8.5 pp, though above England (82.8%). Cancer prevalence is 4.0% (2,406 patients; England 3.8%, Swale 4.3%). This dose drop may reflect recall timing, which practice audits could test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of staged cancers in NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384 cases), in line with England (55.3%) but 19.4 pp below the 75.0% national ambition. Known stage was recorded for 63.6% of registered cancers (8,384 of 13,189), trailing England (67.0%). Early diagnosis reflects system-level performance, not PCN delivery. Locally, primary care screening uptake is strong: PCN breast screening reached 73.7% (England 69.9%) and cervical screening was 73.3% (England 66.8%), though Green Porch Medical Partnership recorded 64.3% for cervical screening.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Medway NHS Foundation Trust achieved 81.6% on the 62-day cancer referral to treatment standard, below the 85.0% standard but above NHS Kent and Medway Integrated Care Board (75.9%) and England (71.2%). Maidstone and Tunbridge Wells NHS Trust reached 87.4%, while Mid and South Essex NHS Foundation Trust achieved 50.2%. On the 28-day faster diagnosis standard, Medway NHS Foundation Trust reached 77.8% (standard 75.0%, ICB 76.8%, England 79.3%). Diagnostic 6-week waits at Medway NHS Foundation Trust were 0.7% for MRI and 0.0% for CT (England 21.4% and 9.9%). These acute figures reflect provider performance rather than PCN delivery.
| Pathways within standard (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 81.78 | 67.45 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 98.35 | 81.88 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 87.43 | 50.25 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | England |
|---|---|---|---|---|
| MRI | 0.68 | 0.92 | 23.35 | 21.40 |
| CT | 0.00 | 0.51 | 6.07 | 9.92 |
| Echocardiography | 36.62 | 2.57 | 65.05 | 28.48 |
| Colonoscopy | 1.88 | 19.80 | 64.09 | 30.83 |
| Gastroscopy | 3.32 | 24.03 | 59.76 | 29.02 |
| All 15 DM01 tests | 14.20 | 6.42 | 41.54 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026, provisional Community Services Dataset records show adults aged 65 and over accounted for 65.8% of community contacts among Swale borough residents (138,250 of 210,170 contacts). These figures reflect borough-level community activity rather than Sittingbourne PCN delivery, highlighting that older adults represent the majority of local community-service demand.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, England overall QOF achievement was 92.5%. Practice achievement ranged from 89.0% at The Chestnuts Surgery to 94.5% at The Meads Medical Practice. On vaccination and immunisation, England averaged 55.2%, while practice achievement spanned 44.3 pp, from 20.1% at Green Porch Medical Partnership to 64.4% at The Chestnuts Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Grovehurst Surgery | 107 | 18.6 | 43.3% | 58.6% | 78.4% |
| Memorial | 109 | 14.6 | 28.6% | 66.1% | 75.6% |
| Meads Medical | 112 | 13.3 | 32.4% | 70.2% | 67.5% |
| Chestnuts | 112 | 20.7 | 27.2% | 78.9% | 64.5% |
| Medic Care | 128 | 0.0 | 35.6% | 62.7% | 59.1% |
| Green Porch | 108 | 15.7 | 36.8% | 74.9% | 54.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year trends lag England across 11 measures despite rapid gains in diabetes control
Three-year changes trail England on 11 measures. The widest relative lags are in heart failure reviews, which fell 1.5% (England +8.7%, Swale +20.1%), dementia prevalence, which fell 3.9% (England +6.0%), and learning disability prevalence, which fell 0.2% (England +5.4%). Conversely, three-year gains occurred in breast screening coverage (+31.4% versus England +8.4%) and diabetes HbA1c control without frailty (+10.2% versus England +4.4%, reaching 54.8%). This divergence is consistent with varying recall or review routines between clinical domains, which local register audits could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Dementia register
Learning disability register
COPD register
BP control, 80+
Breast screening (53-70)
Diabetes HbA1c control
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Swale | Asset | PCN | Swale |
|---|---|---|---|---|---|
| Care homes (catchment) | 23 (528 beds) | n/a | Schools (catchment) | 78 | n/a |
| Children's centres | 4 | 10 | Places of worship | 38 | 70 |
| Libraries | 1 | 5 | Food banks (VCS) | 3 | 5 |
| Day centres (VCS) | 1 | 9 | Children and young people (VCS) | 4 | 20 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 8 | 15 |
| Primary academies | 17 | 31 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Pre-school MMR second dose catch-up
In Q1 2025/26, MMR coverage at age 5 (cohort 185) dropped 6.5 pp from 93.0% (dose 1) to 86.5% (dose 2), sitting 8.5 pp below the 95.0% target. For discussion: audit age-five cohorts for overdue second MMR doses and offer flexible catch-up slots, prioritising practices with the widest drop-off. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Structured annual asthma review recall
Annual asthma reviews reached 62.5% vs 63.4% in Swale and 65.7% in England, leaving 1,294 (about 1,300) of 3,454 register patients unreviewed. For discussion: run a single-template asthma recall combining inhaler checks with flexible or after-school slots across high-volume and high-Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Lipid-modifying prescribing formulary review
In 2026, lipid-modifying drugs cost £2.50 per item vs £2.32 in Swale, £1.90 in ICB and £1.86 in England (£54,588 more than England's unit cost across 85,293 items). For discussion: conduct a PCN pharmacist review of lipid-modifying prescribing to align formulary choices while sustaining high-risk lipid-lowering initiation. Low cost, quick to run.
Evidence base: tracks pharmacological uptake of hypertension case-finding and BP control; rising volume with falling admissions is the success signal.
Policy anchor: Core20PLUS5 adults: hypertension case-finding and optimal management (CVD); Modern service frameworks for CVD, frailty and dementia, severe mental illness.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric primary care capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Targeted Core twenty outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older hypertensive patient review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Option 1 · Pre-school MMR second dose catch-up (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Lipid-modifying prescribing formulary review (p12) | Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026 · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
